PMC66 THE ADVANTAGES OF A CENTRALIZED DISSEMINATION STRATEGY FOR HEALTH OUTCOMES INSTRUMENTS AND THEIR TRANSLATIONS: A CASE EXAMPLE WITH THE ZARIT BURDEN INTERVIEW (ZBI)
Anfray C 1 , Emery MP 1 , Zarit S 2 1 MAPI Research Trust, Lyon, France, 2 Pennsylvania State University, University Park, PA, USA OBJECTIVES: Since December 2007 the Zarit Burden Interview is centrally distributed under the control and with the collaboration of its developer. Our objective was to demonstrate the efficacy of such process by comparing the information about the instrument translations retrieved through a classical literature search with the one provided through the centralized distribution process. METHODS: We searched Medline, Embase and PsychInfo with the keywords: Zarit, caregiver, burden, interview, translation, language, and validation. The articles were tabulated according to the language used in the study, the country of reference, and the number of teams in each country using the ZBI. The search procedure and the information retrieved were then compared with those obtained through the distribution centre. RESULTS: The literature search resulted in 106 articles of which 15 concerned ZBI derivatives, and 9 the original US version. Out of the remaining papers, we identified 59 local teams corresponding to 20 countries and 12 languages. Only 9 articles concerned the psychometric validation of the ZBI in different countries. For most countries, there was no way to check item correspondence across translations or to identify whether one version was the same one used across all teams, increasing the doubt of having multiple translations for one country and language (e.g. Spain-n 9 teams). There was no clear information about the translations' validation status. Contrarily, the information provided through the distribution center led to the quick identification of 33 translations, certified by the developer. Information about copyright, conditions of use and methodology of translation was provided. CONCLUSIONS: Findings indicate that information retrieved through a centralized distribution is more reliable and less time consuming than a search using classical tools. Promoting a controlled centralized system with instrument developers' input will facilitate access to comprehensive information, and will contribute to meet health authorities' requirements of evidence-based information.
PMC67 LINGUISTIC ADAPTATION OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) INTO ENGLISH
Ruiz MA 1 , Rejas J 2 , Pardo A 1 , Soto J 2 1 Universidad Autónoma de Madrid, Madrid, Spain, 2 Pfizer Spain, Madrid, Spain OBJECTIVES: Treatment Satisfaction (SATMED-Q) is a generic PRO instrument measuring Treatment satisfaction with medicines in chronic health conditions, originally developed in Spanish, with known good psychometric properties. A new English version has been produced and linguistically tested. METHODS: The original version was translated into English by the Spanish speaking authors and used as reference for further versions. Two independent English native translators created two translated versions and a harmonised version was produced. The harmonized version was tested by three clinicians in a pilot sample of 20 chronic patients. Suggested modifications were introduced and a final version was shaped. The final version was compared with the reference translation and back-translated into Spanish by two other independent translators native in Spanish. RESULTS: Meaningful differences were found between the two translations, especially when referring to undesirable effects, medication-treatment, disease-illness-medical condition, leisure and labour. Slight dif-disease-illness-medical condition, leisure and labour. Slight dif-leisure and labour. Slight differences were also found on the words used to anchor the Likert response scales. Suggestions from the pilot sample advised to introduce examples accompanying questions about physical activity, free time activities, daily activities and personal hygiene, in order to illustrate questions. Nevertheless, the questionnaire was found easy to answer and to understand, and completion times were similar to those found with the original instrument. CONCLUSIONS: An English version of the SATMED-Q questionnaire is now available with linguistic validity ensured. Although psychometric properties should now be assessed, this new version allows beginning the cultural validation process and can be safely used as a bridge instrument towards other languages.
PMC68 CORRELATION BETWEEN ADHERENCE RATES MEASURED BY MEDICATION EVENT MANAGEMENT SYSTEM AND SELF-REPORTED QUESTIONNAIRES: A META-ANALYSIS
Shi L 1 , Liu J 1 , Walker PD 1 , Fonseca V 1 , Kalsekar A 2 , Pawaskar MD 2 1 Tulane University, New Orleans, LA, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: This study performed meta-analysis examining the correlations of measurements of medication adherence (medication event monitoring system [MEMS] and self-reported questionnaires) using published study reports. METHODS: The literature search was performed from 1980-2009 using PubMed, PubMed In Process and Non-Indexed, OVID MEDLINE, PsycINFO (EBSCO), CINAHL (EBSCO), OVID HealthStar, EMBASE (Elsevier), and Cochrane Databases. The following search terms were used: patient compliance, medication adherence, treatment compliance, drug monitoring, drug therapy, electronic, digital, computer, monitor, monitoring, drug, drugs, pharmaceutical preparations, compliance, and medications. Studies were included if the correlation coefficients [Pearson correlation coefficient (rp) or Spearman rank correlation coefficient (rs)] between adherences measured by both MEMS and self-reported questionnaires were available or could be calculated. A meta-analysis was conducted to pool the correlation coefficients using random-effect model. RESULTS: A total of 11 studies (N 1684 patients) met the inclusion criteria. The mean of adherence measured by MEMS was 74.9%, ranging from 53.4% to 92.9% and 84.0% by self-reported questionnaire, from 76.5% to 93.5%. The correlation between adherence measured by MEMS and self-report questionnaires ranged from 0.24 to 0.87. Seven (63.6%) articles reported rp values whereas 4 studies (36.4%) had rs values. The combined effect size for 11 studies was 0.45 (p 0.001, 95% confidence interval [95% CI]: 0.34-0.56). The subgroup meta-analysis on the studies reporting rp and rs correlation revealed the effect size 0.46 (p 0.001, 95% CI: 0.33-0.59) and 0.43 (p 0.001, 95% CI: 0.23-0.64), respectively. CONCLUSIONS: The correlation between adherence measured by MEMS and self-reported questionnaires tends to be moderate. Therefore, self-reported questionnaires give good estimate of patient medication adherence. However, MEMS and self-reported questionnaire should be used complementary to get accurate measure for patient adherence.
PMC69 EXAMINING MASLOW'S HIERARCHICAL THEORY OF NEEDS BY USING THE ITEMS OF THE WHOQOL-BREF
Yao G, Lin WL National Taiwan University, Taipei, Taiwan OBJECTIVES: Over the last few decades, many theories have been developed for the basic needs of human beings. Specifically, Maslow's hierarchical model offered a sounder theoretical basis for theory of needs. The aim of this research was to examine whether the items of quality of life (based on the WHOQOL-BREF Taiwan version)
the items of quality of life (based on the WHOQOL-BREF Taiwan version) fit with the framework of Maslow's hierarchy of needs. METHODS: This study used This study used 13,008 participants aged from 20 to 65 from the 2001 National Health Interview Survey (NHIS) in Taiwan. The items of the WHOQOL-BREF were categorized according to Maslow's five hierarchical levels of needs: physiological needs, safety needs, physiological needs, safety needs, love and belonging needs, esteem needs and self-actualization needs. Structural equa-Structural equation modeling (SEM) was conducted to test the hierarchical model. RESULTS: The results showed that the model of Maslow's hierarchy of needs did not fit the real data well if all of the items of the WHOQOL-BREF Taiwan version were used. However, Taiwan version were used. However, were used. However, after deleting several misfit items, the model can be fitted well. In general, the deleted , the model can be fitted well. In general, the deleted the model can be fitted well. In general, the deleted items were comparatively far from the definition of Maslow's hiererchical model.
CONCLUSIONS:
The study showed that partial items from the WHOQOL-BREF fit
The study showed that partial items from the WHOQOL-BREF fit he study showed that partial items from the WHOQOL-BREF fit partial items from the WHOQOL-BREF fit with the framework of Maslow's hierarchy of needs. In conclusion, Maslow's hierarchy of needs was partially supported by the WHOQOL-BREF.
PMC70 CLASSIFYING PATIENT REPORTED OUTCOMES: DEVELOPMENTS IN THE FIELD SUGGEST A NEW TAXONOMY
Lloyd A 1 , Bridges JF 2 , Johnson FR 3 1 Oxford Outcomes Ltd, Oxford, UK, 2 Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 3 RTI Health Solutions, Research Triangle Park, NC, USA OBJECTIVES: The FDA proposed the term 'patient reported outcomes' in 2001 which grouped concepts such as quality of life (HRQL), satisfaction and preference together in terms of their role in regulatory approval. Since then there have been notable developments in the field, not least the much wider use of stated preference methods such as conjoint analysis. METHODS: ISPOR's Patient Preference Conjoint Analysis Working Group convened a team to develop a new taxonomy to characterise the different approaches used to capture patient based data. A thorough review of different patient reported methods was undertaken, and based upon discussion and further expert review, a taxonomy of methods based was developed. RESULTS: Several groups of methods emerged from the review which reflected both the underlying data that the method produces and also the audience of the data-regulators, payers, policy makers and decision makers. Group 1 (Classic PRO) includes different psychometric approaches, commonly based upon Likert scale responses. This group includes measures of HRQL, symptoms and treatment satisfaction. Group 2 (Stated preference) describes ordinal methods including conjoint analysis (discrete choice, graded pairs)and willingness to pay methods. Group 3 (Cardinal utility) describes cardinal methods of capturing health outcomes often used in economic evaluation. Each group of methods also has naturally different audiences. CONCLUSIONS: The FDA's simple classification of measures as PROs does not reflect the diversity and applications of patient reported data. The proposed taxonomy we believe reflects important differences in methods and also the different uses of data.
PMC71 THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND THE ROLE OF THE QALY
Schlander M 1 , Richardson J 2 1 Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany, 2 Monash University, Clayton, Victoria, Australia The quality-adjusted life year (QALY) is a unit of measurement which combines the length and quality of life in a way which reduces the number of dimensions which must be taken into account in an economic evaluation. In simple cost utility analysis (CUA) the problem of allocating scarce resources is reduced to two steps: ranking projects by their cost per QALY and deciding upon a threshold cost per QALY above which projects will not be funded. Over time there has been increasing dissatisfaction with the perceived excessive simplicity of the approach. Partly this has arisen over technical questions: which instrument should be used to measure QALYs (the SG, TTO, etc.); should the QALY be replaced by the healthy-year equivalent (HYE)-is there additive separability between health states; are valid QALY league tables achievable. However there has been also increased questioning of the value basis of the QALY. Should 'utility' incorporate an individual or social perspective (like the person trade-off, PTO); should economics revert to the earlier concept of hedonic, rather than preference / utility (i.e., subjective well-being), but, perhaps most fundamentally, can QALYs be abstracted from other values relating to the distribution of benefits between patients with dissimilar problems, and disregard characteristics of services except when they impact upon utility, social well-being (SWB) or some other uni-dimensional value. Apart from normative concerns, there are an increasing number of empirical studies on societal preferences for health care resource allocation, indicating that the QALY maximization hypothesis must be considered as falsified. The broad range of documented 'contextual' variables implies that a uniform 'social value' of a QALY does not exist, and suggests that projects designed to determine the dollar value of a QALY will either fail or mislead policy. However, adherence can only partially be explained by clinical and these PRO variables alone. Our objective was to develop a generic Acceptability measure assessing how patients balance out between advantages and disadvantages of long-term treatments. It could be used in future adherence studies. METHODS: A literature review was conducted in biomedical databases using keywords related to acceptability, perceptions, motivations and barriers linked to treatment, allowing the initial conceptual model of Acceptability to be developed. Exploratory interviews were performed with 5 pharmacists and 18 patients. They were recorded, transcribed word-for-word and systematically analysed in order to complete the initial conceptual model. Items of the ACCEPT© questionnaire were generated in French for each concept identified, using patients' words. The resulting test version was tested for relevance and comprehension with 5 patients, and revised accordingly; the new version was tested on a second set of 5 patients and revised to create the pilot version of the ACCEPT© questionnaire.
PMC72

DEVELOPMENT OF THE ACCEPT© QUESTIONNAIRE TO ASSESS ACCEPTABILITY OF LONG TERM TREATMENTS: QUALITATIVE STEPS
RESULTS:
In the test version, items generated for each concept identified were organised into 6 sections: drug characteristics, duration, constraints, side-effects, efficacy and global acceptability of treatment. Except a few items that were modified or deleted following patients' suggestions and some minor modifications in the answer choices, the questionnaire was globally very well accepted, easy to complete, and considered relevant and appropriate by patients. The pilot version of the ACCEPT© questionnaire contains 32 questions divided into the same 6 sections as the test version. CONCLU-SIONS: The comprehension tests confirmed the existence of the previously hypothesised concept of treatment Acceptability. The ACCEPT© questionnaire will allow the Acceptability of a great variety of long-term treatments to be assessed, while being a specific instrument making sense to each individual.
PMC73 DIFFERENT STUDY RESULTS OF UTILITIES IN RELATION TO THE DOCUMENTING METHOD USED AND THE GUARANTEE OF LEGALLY COMPLIANT IQWIG RECOMMENDATIONS WITHIN THE FRAMEWORK OF A COST-BENEFIT ASSESSMENT
Dintsios CM, Volz F, Seidl A Institute for Quality and Efficiency in Health Care, Cologne, Germany OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) assesses the benefit and costs of drugs by considering their affordability and reasonableness from the insurants' viewpoint. IQWiG forwards its assessments to the German Federal Joint Committee (G-BA) in the form of recommendations, which may be used in establishing ceiling prices for drug innovations. Within the framework of its methods proposal, IQWiG does not negate an intra-indication-related application of QALYs for cost-benefit assessments. However, depending on the methods applied and the target populations surveyed, different results can be generated for evaluating states of health. No international standard exists for a preferred method. METHODS: After performing a systematic literature search to identify studies in which various methods for documenting benefit were applied and different target populations were investigated, selected studies are presented, whose incremental cost-utility-ratios have an (extremely) wide scatter related to the documenting. Depending on the documenting method, indication-dependent trends are investigated for effect size and direction of QALYs. RESULTS: The studies identified show that the variation in methods for documenting QALYs even within the same intervention trial considerably reduces its comparability. It is also not easily possible for decision-makers to make a decision based on these results. The documenting methods used clearly create different constructs that apparently display different levels of responsiveness in the same indication (e.g. rheumatoid arthritis, sleep apnoea, macular degeneration, oral anticoagulation). In the inter-indication comparison, a clear trend could not be determined for the effect size in the results in relation to the documenting methods used. CONCLUSIONS: If the legal conditions are satisfied and a consistent decision using cost-utility analyses in one indication area is possible, the documenting method for utilities must be standardised. This could be directed indication-specific towards an optimum correspondence with the responsiveness of validated, disease-specific quality of life documenting instruments.
PMC74 WHICH HEALTH ECONOMIC APPROACHES FOR WHICH DECISION-MAKING SUPPORT IN METASTATIC CANCER ? A LITERATURE REVIEW AND FRENCH EXPERT OPINIONS
Baffert S 1 , Alfonsi A 2 , Florentin V 2 , Livartowski A 1 1 Institut Curie, Paris Cedex 05, France, 2 Roche, Neuilly sur Seine, France Conventional health economic tools are not adapted to the very specific problems of metastatic cancer treatment. The objective of this study was to analyze the methodological tools used in published economic evaluations for metastatic breast cancer (empirical studies) and for all metastatic cancer treatments (methodological studies). Results of a systematic literature search (Medline, Embase, Cochrane Library, Pascal, HTA databases) since 1990 were completed by expert interviews (oncologists, health economists, decision-makers). 535 abstracts were screened and 80 selected, excluding: clinical trials with no economic analysis, alternative treatments to chemotherapy, early stages of cancer, any metastatic cancer with no specific and/or original methodology and/or endpoints. According to a pharmacoeconomic quality checklist, 37 were analyzed. The review showed a majority of studies in breast cancer with low level of evidence and only two prospective studies. More than half of the studies were cost-utility analyses. Endpoints combine quality of life and other indicators: QALY (Quality-Adjusted Life Years), Q-TWiST (Quality-Adjusted Time Without Symtoms and Toxicity), QAPFYs (Quality-Adjusted Progression-Free life Years), QADs (Quality-Adjusted Days of life). We did not find any specific criterion to the metastatic state. Experts recommend the use of multi-dimension criteria comprising direct and indirect costs, efficacy and quality of life data integrating patient preferences; thresholds of resource allowance should be defined according to treatment strategies and population subgroups (performance status, age, illness severity). This study underlines the need to develop tools for poor prognosis diseases and raises the issue of the integration of economic rationality in the health care decisions in France. Although some countries have chosen arbitrations (QALY, Efficiency Frontier per pathology), France has not yet chosen a validated method for resources allocation.
